Aspen willing to alter production for Covid-19 needs
The pharmaceutical manufacturer urges people not to hoard cold and flu medications, saying its supply chain is robust
JSE-listed Aspen Pharmacare will adjust production schedules at its manufacturing plants to ensure supplies of critical medicines, such as antibiotics, should SA’s Covid-19 outbreak trigger a sudden increase in demand, according to CEO Stephen Saad.
There is no vaccine or cure for the coronavirus that causes Covid-19, but there could well be a surge in demand for products such as antibiotics to treat secondary infections, he said. Aspen has also given the government an undertaking that it will alter its production plans to ensure continued supplies of other critical drugs, including those used for chronic conditions, should the need arise, he said...